Adicet Bio Reports $21.4 Million Net Loss in Q2 2026, Improves Operating Expenses by 31%

Adicet Bio, Inc. reported a net loss of $21.4 million for the second quarter of 2026, a 32% improvement compared to a net loss of $31.2 million in the same period of the previous year. The company's total operating expenses decreased by 31% to $22.3 million, down from $32.4 million in the prior year, primarily due to a significant reduction in research and development costs, which fell by 35% to $18.5 million. This decline was attributed to lower costs associated with contract research organizations (CROs) and a decrease in personnel expenses due to a reduced headcount.

For the first half of 2026, Adicet reported a net loss of $41.6 million, a decrease of 30% from the $59.4 million loss recorded in the first half of 2025. Total operating expenses for this period were $43.9 million, down from $62.3 million in the prior year. The company’s cash, cash equivalents, and short-term investments totaled $118.2 million as of June 30, 2026, providing a sufficient runway to fund operations for at least the next twelve months.

Adicet continues to focus on its lead product candidate, prula-cel, an allogeneic gamma delta T cell therapy targeting autoimmune diseases. The company has received FDA clearance for its IND application for prula-cel in lupus nephritis and is advancing clinical trials for multiple indications, including systemic lupus erythematosus and systemic sclerosis. The company plans to initiate a pivotal trial for prula-cel in lupus nephritis in the second half of 2026, pending regulatory clearance.

In addition to prula-cel, Adicet is developing ADI-212, a next-generation gene-edited therapy targeting prostate-specific membrane antigen, with plans to submit a regulatory filing for a clinical trial in the third quarter of 2026. The company is also exploring collaborations and partnerships to enhance its product pipeline and expand its market presence, particularly in the U.S. and China.

Despite the positive developments, Adicet acknowledges significant risks, including reliance on the success of prula-cel, the challenges of clinical trials, and the need for substantial additional financing to support ongoing operations and product development. The company has indicated that it may need to raise additional capital through equity or debt financing, collaborations, or other arrangements to continue its business strategy effectively.